Evidence map›Paper›PMID 41907818›Full record

ArticleKidney international reports2026

Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy.

Yousra Cheddadi, Mounir El Maï, Vesna Brglez, Sarah Nahon Carzo, Marion Cremoni, Maxime Teisseyre, Barbara Seitz-Polski

Registry-linked trialAbstract read
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07702981 (Immunophenotyping Profiling in Patients With Nephrotic Syndrome), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07702981 completednot on this map

Immunophenotyping Profiling in Patients With Nephrotic Syndrome: Emphasis on the Diagnostic and Prognostic Value of Immune Cells in the Different Phenotypes of Nephrotic Syndrome.

Typeobservational_patient_registrySponsorUniversity Hospital, IoanninaRan2023 to 2026Enrolled40ConditionsMembranous Nephropathy, Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)ArmsRituximab (MABTHERA® or RITUXAN®)., Corticosteroids (CS)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yousra CheddadiLaboratoire d'Immunologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Nice, Nice, France.
Mounir El MaïLaboratoire d'Immunologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Nice, Nice, France.
Vesna BrglezLaboratoire d'Immunologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Nice, Nice, France.
Sarah Nahon CarzoLaboratoire d'Immunologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Nice, Nice, France.
Marion CremoniLaboratoire d'Immunologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Nice, Nice, France.
Maxime TeisseyreLaboratoire d'Immunologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Nice, Nice, France.
Barbara Seitz-PolskiLaboratoire d'Immunologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Nice, Nice, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41907818
PMCPMC13022648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.